In terms of immune microenvironmental pathways, LDLR promoted immune inflammatory processes in most tumors, and in breast cancer LDLR promoted cell cycle processes and inhibits tumor immunogenesis (Fig. 7B). The gene discussed is LDLR; the disease is breast carcinoma.